JP2018525332A5 - - Google Patents

Info

Publication number

JP2018525332A5

JP2018525332A5 JP2017565185A JP2017565185A JP2018525332A5 JP 2018525332 A5 JP2018525332 A5 JP 2018525332A5 JP 2017565185 A JP2017565185 A JP 2017565185A JP 2017565185 A JP2017565185 A JP 2017565185A JP 2018525332 A5 JP2018525332 A5 JP 2018525332A5

Authority

JP

Japan

Prior art keywords

amino acid

seq

acid sequence

antibody

hvr

Prior art date

2016-06-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims description 259
• 239000000203 mixture Substances 0.000 claims description 53
• 238000000034 method Methods 0.000 claims description 51
• 238000004519 manufacturing process Methods 0.000 claims description 46
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
• 206010016654 Fibrosis Diseases 0.000 claims description 32
• 201000010099 disease Diseases 0.000 claims description 32
• 230000004761 fibrosis Effects 0.000 claims description 32
• 230000003176 fibrotic effect Effects 0.000 claims description 29
• 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 claims description 25
• 102000051056 human SIGLEC8 Human genes 0.000 claims description 25
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 23
• 239000003814 drug Substances 0.000 claims description 16
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 15
• 239000000556 agonist Substances 0.000 claims description 12
• 230000000694 effects Effects 0.000 claims description 10
• 238000006467 substitution reaction Methods 0.000 claims description 9
• 206010039710 Scleroderma Diseases 0.000 claims description 8
• 229940079593 drug Drugs 0.000 claims description 8
• 210000002950 fibroblast Anatomy 0.000 claims description 8
• 230000003434 inspiratory effect Effects 0.000 claims description 8
• 230000004199 lung function Effects 0.000 claims description 8
• 230000001575 pathological effect Effects 0.000 claims description 8
• 210000003630 histaminocyte Anatomy 0.000 claims description 7
• 230000008595 infiltration Effects 0.000 claims description 7
• 238000001764 infiltration Methods 0.000 claims description 7
• 108010006654 Bleomycin Proteins 0.000 claims description 6
• 229960001561 bleomycin Drugs 0.000 claims description 6
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 6
• 210000004072 lung Anatomy 0.000 claims description 5
• 208000024891 symptom Diseases 0.000 claims description 5
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 4
• 201000001320 Atherosclerosis Diseases 0.000 claims description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
• 102000008186 Collagen Human genes 0.000 claims description 4
• 108010035532 Collagen Proteins 0.000 claims description 4
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
• 102000004127 Cytokines Human genes 0.000 claims description 4
• 108090000695 Cytokines Proteins 0.000 claims description 4
• 206010019668 Hepatic fibrosis Diseases 0.000 claims description 4
• 208000024934 IgG4-related mediastinitis Diseases 0.000 claims description 4
• 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
• 208000002805 Mediastinal fibrosis Diseases 0.000 claims description 4
• 206010028980 Neoplasm Diseases 0.000 claims description 4
• 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims description 4
• 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 4
• 206010072207 Splenic fibrosis Diseases 0.000 claims description 4
• 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
• 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
• 241000700605 Viruses Species 0.000 claims description 4
• 238000009825 accumulation Methods 0.000 claims description 4
• 125000000539 amino acid group Chemical group 0.000 claims description 4
• 201000011510 cancer Diseases 0.000 claims description 4
• 230000009787 cardiac fibrosis Effects 0.000 claims description 4
• 229920001436 collagen Polymers 0.000 claims description 4
• 239000012634 fragment Substances 0.000 claims description 4
• 239000007943 implant Substances 0.000 claims description 4
• 230000004941 influx Effects 0.000 claims description 4
• 206010028537 myelofibrosis Diseases 0.000 claims description 4
• 210000000651 myofibroblast Anatomy 0.000 claims description 4
• 210000000440 neutrophil Anatomy 0.000 claims description 4
• 201000002793 renal fibrosis Diseases 0.000 claims description 4
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
• 230000020411 cell activation Effects 0.000 claims description 3
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
• 230000002265 prevention Effects 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• 230000007423 decrease Effects 0.000 claims 1
• 208000035475 disorder Diseases 0.000 claims 1
• 230000004044 response Effects 0.000 claims 1
• 150000001720 carbohydrates Chemical group 0.000 description 6
• 230000002206 pro-fibrotic effect Effects 0.000 description 5
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 4
• 206010012689 Diabetic retinopathy Diseases 0.000 description 2
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
• 208000010412 Glaucoma Diseases 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 206010035742 Pneumonitis Diseases 0.000 description 2
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
• 206010038934 Retinopathy proliferative Diseases 0.000 description 2
• 208000036866 Vitreoretinopathy Diseases 0.000 description 2
• 206010064930 age-related macular degeneration Diseases 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• 201000003142 neovascular glaucoma Diseases 0.000 description 2
• 229920001542 oligosaccharide Polymers 0.000 description 2
• 150000002482 oligosaccharides Chemical class 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 238000009423 ventilation Methods 0.000 description 1